As pharmaceutical global spending is predicted to increase by 29-32% by 2020*, the need for access to cheaper alternative medicines and technology is essential. The use of generics is on the rise and it’s expected that by 2020, 88%* of total medicine use will be attributed to generics, over the counter, and non-original branded products. Source:http://bit.ly/1jb3s88
This year’s agenda will have a strong focus on the future of pricing and reimbursement. Other key topics include:
- Updates on AMNOG and its implication on pricing and reimbursement
- How biosimilars are affecting your pricing strategy
- Capture on emerging markets’ regulatory framework to adapt your market access and P&R models
- Orphan drugs using recent examples to highlight the impact on pricing
- Cancer drug funding and budget cuts in the UK
- Innovative solutions beyond the pill
- Japanese and Turkish regional updates
